Immunoglobulin E (IgE) recognizing peanut allergens (Peanut-specific IgE)

Immunoglobulin E (IgE) antibodies specific to peanut allergens, particularly the storage proteins Ara h 1, Ara h 2, and Ara h 3, are the primary mediators of peanut-induced Type I hypersensitivity reactions (Source: PubMed, PMID: 31202364). In sensitized individuals, these antibodies are produced by B cells and circulate in the blood or bind to high-affinity FcεRI receptors on the surface of mast cells and basophils. Upon ingestion of peanut proteins, the allergens cross-link these membrane-bound IgE molecules, triggering the immediate release of inflammatory mediators such as histamine and leukotrienes (Source: StatPearls, 2023). This biological cascade can lead to clinical symptoms ranging from mild urticaria to life-threatening systemic anaphylaxis. Therapeutic strategies targeting these antibodies include the use of Omalizumab, which sequesters free IgE to prevent cellular activation, and oral immunotherapy (OIT), which aims to modulate the immune system's sensitivity to the allergen over time (Source: FDA, 2024). Monitoring peanut-specific IgE levels, especially those directed against the Ara h 2 component, is a critical diagnostic tool for assessing the risk and severity of peanut allergy (Source: JACI, 2021).

Other names

Peanut-specific IgEsIgE to peanutArachis hypogaea-specific IgEAnti-peanut IgE

Omalizumab is a monoclonal antibody that binds to the Fc region of free IgE, specifically the Cε3 domain, preventing it from binding to the high-affinity IgE receptor (FcεRI) on mast cells and basophils (Source: StatPearls, 2023). This sequestration reduces the density of receptors on effector cells and prevents allergen-induced cross-linking. Oral immunotherapy (OIT), such as Palforzia, works by gradual exposure to peanut allergens to induce desensitization, which is characterized by a shift in the immune response from IgE-mediated hypersensitivity to an increase in allergen-specific IgG4 and regulatory T-cell activity (Source: JACI, 2020).